rss

Recent eLetters

Displaying 1-10 letters out of 741 published

  1. Oxygen is toxic during reoxygenation in STEMI patients as well as in other clinical conditions

    Nehme and coworkers tested out the effect of air versus oxygen on myocardial injury in ST-elevation myocardial infarction (STEMI).1 When administered in the first 12 hours after STEMI oxygen was associated with a dose-dependent increase in troponin and creatine kinase. In 2015 the same group of investigators published a study in Circulation showing that air instead of oxygen supplementation in STEMI led to improved outcome. The conclusions of these two studies seem to be that supplemental oxygen therapy in patients with STEMI but without hypoxia may increase early myocardial injury and is associated with larger myocardial infarct size assessed at 6 months. In 1980 we were the first to suggest that due to production of oxygen free radicals air could be better than oxygen supplementation during reoxygenation.2 During the next 30 years we performed a series of studies demonstrating that air compared to 100% oxygen caused significantly less oxidative stress and less myocardial and kidney injury, and resulted in higher survival rates in newborn infants needing resuscitation at birth. In animal studies we demonstrated that 100% oxygen induced injury or inflammation of several organs as the brain and heart.3,4 We also have worked intensively with the basic mechanisms explaining such findings. Based on these and other studies international recommendations for newborn resuscitation were changed in 2010 from starting with 100% oxygen to air.

    We have always been surprised that colleagues in adult medicine apparently have not been aware of these results. The mechanisms of reoxygenation injury are probably similar in adults as in newborn. We are therefore delighted that Nehme et al1 and Stub et al performed their studies, although 30 years after we challenged the present oxygen dogma.

    It is therefore with surprise we don't find any references in their publications 1 to our basic experimental and clinical studies. Thirty years of extensive research with internationally acknowledged translational results have not been credited by the authors, reviewers as well as the editors responsible for publishing these results. We truly believe that now is the time when adult medicine should recognize progress in neonatal medicine which has helped unravel pathophysiological mechanisms that have improved the survival and quality of life of human beings independently of their age.

    References

    1. Nehme Z, Stub D, Bernard S, et al. Effect of supplemental oxygen exposure on myocardial injury in ST- elevation myocardial infarction. Heart 2016;102: 444-51 2. Saugstad OD, Aasen AO. Plasma hypoxanthine concentrations in pigs. A prognostic aid in hypoxia. Eur Surg Res 1980;12:123-9. 3. Saugstad OD, Ramji S, Vento M. Resuscitation of depressed newborn infants with ambient air or pure oxygen: a meta-analysis. Biol Neonate 2005;87:27-34 4. Saugstad OD. Resuscitation of newborn infants: from oxygen to room air. Lancet 2010;376:1970-1

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response
  2. Signficance of Inverse Prognostic Value of Post-PCI FFR in Patients with NSTEMI

    I read the article by Kasula and colleagues with great interest. I firmly believe that this is a novel finding and of great clinical significance (1).

    Utility of Fractional flow reserve (FFR) is firmly established in stable coronary artery disease but has been widely debated in patients with acute MI particularly in the culprit vessel (2, 3). FFR measurements require maximal coronary hyperaemia which may be less readily achieved in patients with acute coronary disease because of coronary microvascular dysfunction. This in turn may result in a falsely higher FFR value. This will be of particular concern while assessing FFR value post-PCI since coronary stenting of a 'hot' culprit lesion in acute coronary syndrome would inevitably carry risk of some distal embolization which may further exacerbate this issue. Since, microvascular obstruction carries a poor prognosis, a direct (in contrast to an inverse relationship) relationship between post-PCI FFR value and adverse outcome would have supported this theoretical limitation of FFR in patients with MI (4). However, it was reassuring to see that these concerns appear unfounded in the current study. The fact that FFR value had an inverse relationship with future adverse events is an in- direct evidence that FFR value is still valid even in culprit vessel in patients with NSTEMI.

    References: 1) Clinical and prognostic value of poststenting fractional flow reserve in acute coronary syndromes

    2) Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J, Koolen JJ, Koolen JJ. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med 1996;334:1703-1708.

    3) Tonino P.A., De Bruyne B., Pijls N.H., et al; Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213-224

    4) Fearon W.F., Low A.F., Yong A.S., et al; Prognostic value of the Index of Microcirculatory Resistance measured after primary percutaneous coronary intervention. Circulation. 2013;127:2436-2441.

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response
  3. Re:T1 Mapping with CMR: an emerging clinical biomarker

    We thank Ripley and colleagues for their interest in our paper and agree that T1 mapping with CMR is an emerging imaging biomarker that is increasingly being investigated for its potential role in hypertrophic cardiomyopathy and cardiac hypertrophy in general. Convincing data have been published concerning hypertensive heart disease(Hinojar et al., 2015), hypertrophic and dilated cardiomyopathy (Puntmann et al., 2013), transthyretin amyloidosis (Fontana et al., 2014) and Anderson-Fabry disease (Pica et al., 2014). We have not found any specific published data examining the role of T1 mapping in distinguishing ventricular septal bulge in an elderly population from other etiologies of hypertrophy. We therefore decided not to include T1 mapping in our review (Canepa et al., 2016) but concur that this technique may be potentially useful in the evaluation of ventricular septal bulge.

    Canepa, M., Pozios, I., Vianello, P. F., Ameri, P., Brunelli, C., Ferrucci, L., & Abraham, T. P. (2016). Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly. Heart, 102(14), 1087-1094. doi:10.1136/heartjnl-2015-308764

    Fontana, M., Banypersad, S. M., Treibel, T. A., Maestrini, V., Sado, D. M., White, S. K., ... Moon, J. C. (2014). Native T1 Mapping in Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 7(2), 157-165. doi:10.1016/j.jcmg.2013.10.008

    Hinojar, R., Varma, N., Child, N., Goodman, B., Jabbour, A., Yu, C.- Y., Puntmann, V. O. (2015). T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study . Circulation: Cardiovascular Imaging , 8 (12 ).doi:10.1161/CIRCIMAGING.115.003285

    Pica, S., Sado, D. M., Maestrini, V., Fontana, M., White, S. K., Treibel, T., Moon, J. C. (2014). Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance?: Official Journal of the Society for Cardiovascular Magnetic Resonance, 16(1), 99. doi:10.1186/s12968-014-0099- 4

    Puntmann, V. O., Voigt, T., Chen, Z., Mayr, M., Karim, R., Rhode, K., Nagel, E. (2013). Native T1 Mapping in Differentiation of Normal Myocardium From Diffuse Disease in Hypertrophic and Dilated Cardiomyopathy. JACC: Cardiovascular Imaging, 6(4), 475-484. doi:10.1016/j.jcmg.2012.08.019

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response
  4. Expediating the pathway to SVT ablation

    Honarbakhsh et al should be congratulated upon their innovative research in improving the care for patients with arrhythmias. Their paper not only demonstrates an effective community treatment strategy but importantly is cost effective during the current austerity. Potential further cost savings and enhanced patient experiences could be anticipated by encouraging General Practitioners to subsequently refer patients wishing for a curative strategy directly to Electrophysiologists for consideration of an ablation.

    Patients affected by SVTs usually experience frustrating recurrent attendances at Accident and Emergency departments prior to referral to Electrophysiologists, despite our knowledge that ablations are successful in 95% at the first procedure. Similarly, many journeys to the AED are aborted as the symptoms self terminate prior to arrival or have abated by the time of medical review. Thus frequently ECGs fail to capture their arrhythmia and clinch the diagnosis, protracting the time to effective treatment. The PARA group had a statistically significant greater chance of receiving a copy of their ECG (85% v 63%, p-value 0.035) and therefore this often illusive information would have a greater chance of being available for inclusion in the onward referral to the Cardiologist or Electrophysiologist.

    Partnerships between community and tertiary care services can expedite and improve arrhythmia care, reducing some of the burden on over stretched Emergency Departments.

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response
  5. Multilevel analysis of variance and hospital performance in heart failure management

    Dear Editor,

    We have read with interest the article written by Emdin et al (1) using multilevel regression analysis of variance to investigate hospital performance for heart failure management. We were pleased to note that the authors apply and refer to our previous methodological work concerning the use of the Intraclass Correlation (ICC) and Median Odds Ratio (MOR).(2) However, the authors did not consider a recent paper of ours investigating survival after heart failure hospitalization and applying a modern multilevel analytical framework.(3)

    Nevertheless, the article by Emdin et al (1) actually applies a similar way of reasoning that we presented in our previous article.(3) In this respect, we would like to take this opportunity to comment on their study.(1)

    First, much of variation in performance identified by the authors could be attributed to the ward rather than to the hospital level since the ward-level is where the genuine organisational effect could take place. In our recent study we found that the ward ICC (around 5.3%) was much larger than the hospital ICC (0.04%).(3)

    Second, while the issue of confounding, and hence the need to adjust for patient case-mix, is a cause of concern in the case of outcome indicator, it is normally not a concern when it comes to process indicators (4) and the authors should have discussed this aspect.

    Third, the authors used backward stepwise single-level regression to identify the hospital characteristics that "were significantly associated with a better performance score". We think this identification should be based on a priori theory rather than on a posteriori finding of statistical significance. Besides, the use of single level regression analysis for this task is unsuitable as it does not consider the intra- hospital correlation and provides spurious "significant" associations.(2)

    Otherwise we agree with Emdin et al(1) methodological approach and interpretation of the results. However, a reference to our previous article (3) should have been made.

    Kind Regards,

    Nermin Ghith, PHD candidate, Research Unit of Chronic Conditions, Bispebjerg Hospital, Copenhagen.

    Prof. Juan Merlo MD, PhD, Head of the Research Unit for Social Epidemiology, Dept. Clin. Sci.(Malmo), Faculty of Medicine, Lund University, Sweden

    -References

    1. Emdin CA, Conrad N, Kiran A, Salimi-Khorshidi G, Woodward M, Anderson SG, et al. Variation in hospital performance for heart failure management in the National Heart Failure Audit for England and Wales. Heart. 2016.

    2. Merlo J, Chaix B, Ohlsson H, Beckman A, Johnell K, Hjerpe P, et al. A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. Journal of Epidemiology and Community Health. 2006;60(4):290-7.

    3. Ghith N, Wagner P, Fr?lich A, Merlo J. Short Term Survival after Admission for Heart Failure in Sweden: Applying Multilevel Analyses of Discriminatory Accuracy to Evaluate Institutional Performance. PLoS ONE. 2016;11(2):e0148187.

    4. Rubin HR, Pronovost P, Diette GB. The advantages and disadvantages of process?based measures of health care quality. International Journal for Quality in Health Care. 2001;13(6):469-74.

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response
  6. T1 Mapping with CMR: an emerging clinical biomarker.

    Dear Editor,

    We read the educational review on distinguishing ventricular septal bulge (VSB) versus hypertrophic cardiomyopathy (HCM) by Canepa et al[1] with great interest. The authors recognise the increasingly established role of cardiovascular magnetic resonance (CMR) in the assessment of this difficult diagnostic dilemma. They describe the gold standard role of CMR in the quantification of myocardial mass, myocardial fibrosis with late gadolinium enhancement and the morphological and functional imaging of mitral valve abnormalities.

    T1 mapping with CMR is an emerging clinical biomarker for the quantification of myocardial disease. The technique is easily measured, highly reproducible and has recently translated into the clinical pathway[2]. With the addition of gadolinium based contrast agent the extracellular volume (ECV) can also be estimated. T1 mapping is clinically able to identify early phenotypic expression of HCM with both increased native T1 and higher ECV[3] and has been shown to distinguish between early phenotypic expression of athlete hearts vs HCM[4]. We would highly recommend T1 mapping techniques to be performed on all patients undergoing CMR which will aid the differentiation of VSB vs HCM.

    Dr David P. Ripley

    Dr Subhi E. Akleh

    Dr Alison F. Lee

    References: 1. Canepa M, Pozios I, Vianello PF, et al. Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly. Heart 2016;102(14):1087-94. 2. Sado DM, White SK, Piechnik SK, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013;6(3):392-8. 3. Puntmann VO, Voigt T, Chen Z, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging 2013;6(4):475-84. 4. Swoboda PP, McDiarmid AK, Erhayiem B, et al. Assessing Myocardial Extracellular Volume by T1 Mapping to Distinguish Hypertrophic Cardiomyopathy From Athlete's Heart. J Am Coll Cardiol 2016;67(18):2189- 90.

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response
  7. Microcirculation impairment in acute coronary syndrome: It is not always the same story

    We read with great interest the elegant work of Kasula et al. recently published on Heart [1]. The Authors showed that fractional flow reserve (FFR) may be an effective tool to discriminate the long-term functional outcome after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) [1]. This retrospective study included exclusively ACS patients for whom FFR evaluation resulted "flow limiting" (<0.80). All patients were treated with PCI and the main finding of the study was that FFR value after PCI was able to discriminate those at higher risk of adverse events. The Authors concluded that FFR reliably estimates baseline ischemia and its subsequent reduction post-PCI in patients with ACS. We totally agree with the significance of the post-PCI FFR assessment, but any comment regarding the FFR role in the determination of baseline ischemia in ACS patients should not be taken for granted. Recently, Lee et al. showed that deferring the treatment of intermediate coronary stenosis based only on the FFR value, without taking into account the features of coronary microcirculation, exposes the patient to an increase of adverse events [2]. Kasula et al. did not report the long-term outcome of patients for whom FFR result was "no flow limiting" [1]. Accordingly, the conclusion that "FFR alone may be an invaluable tool in identifying ischemia producing lesions" is methodologically incorrect. It is well established that microvascular disfunction may be the result of: i) pre-existing condition (e.g. microvascular angina), ii) chronic damage (e.g chronic kidney disease [3]), iii) acute injury (e.g. ACS) or iv) a mix of these. Therefore, the impairment in the coronary microcirculation may differ significantly across ACS patients. Some patients show a partial impairment that allows an effective adenosine action and then a proper FFR determination. Contrarily, other patients have an extensive damage and FFR assessment may result misleading. For this reason, in our opinion, it seems important to focus our attention on ACS patients with "no flow limiting" FFR assessment. In these cases, the simultaneous assessment of the coronary microcirculation (e.g. index of microcirculatory resistance) may help physicians in the decision-making process [4].

    References

    1. Kasula S, Agarwal SK, Hacioglu Y, et al. Clinical and prognostic value of poststenting fractional flow reserve in acute coronary syndromes. Heart. 2016 Aug 4 doi: 10.1136/heartjnl-2016-309422 2. Lee JM, Jung JH, Hwang D, et al. Coronary Flow Reserve and Microcirculatory Resistance in Patients With Intermediate Coronary Stenosis. J Am Coll Cardiol. 2016 15;67(10):1158-69 3. Tebaldi M, Biscaglia S, Fineschi M, et al. Fractional flow reserve evaluation and chronic kidney disease: Analysis from a multicenter Italian registry (the FREAK study). Catheter Cardiovasc Interv. 2015 Dec 31. doi: 10.1002/ccd.26364 4. Tebaldi M, Biscaglia S, Pecoraro A, et al. Fractional flow reserve implementation in daily clinical practice: A European survey. Int J Cardiol. 2016 15;207:206-7.

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response
  8. Re Larsson et al, Chocolate consumption adn risk fo myocardial infarction: a propspective stusy and meta-analysis

    Comment to the Heart Journal website

    re Larsson et al, Chocolate consumption and risk of myocardial infarction: a prospective study and meta-analysis. The findings of Larsson et al are fascinating and in line with earlier reports of cardio-protective effects of chocolate consumption, especially of dark chocolate. Having noticed this in the literature, a colleague and I were inspired to measure the vitamin D content of dark chocolate, since it was known that curing cocoa beans in the sun was associated with some fungal growth and that fungi synthesize vitamin D2, as evidenced in mushrooms, sometimes irradiated with UV for food fortification, and or-ur pilot study demonstrated remarkably high vitamin D2 content of the various dark chocolate samples examined. The reported benefits may, therefore, be due in part to the contained vitamin D2, since similar protection is currently being found with better vitamin D status, or supplementation. I would be interested to know, therefore, whether the cohorts reported upon happen to have measurements of serum 25(OH)D available that could be assessed for variation with chocolate consumption, and cardiovascular events, which would be of great interest, either way.

    Barbara J Boucher BSc. MD, FRCP. bboucher@doctors.org.uk

    References Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis. BMJ 2011;343:d4488; Response, by Timms PM et al

    Dietary vitamin D?--a potentially underestimated contributor to vitamin D nutritional status of adults? Cashman KD, Kinsella M, McNulty BA, Walton J, Gibney MJ, Flynn A, Kiely M. Br J Nutr. 2014 Jul 28;112(2):193-202.

    The vitamin D activity of cacao shell: The effect of the fermenting and drying of cacao on the vitamin D potency of cacao shell. II. The origin of vitamin D in cacao shell. Knapp AW. Biochem J. 1935 Dec;29(12):2728-35.

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response
  9. Re:It is important to distinguish between HFrEF and HFpEF when interpreting these data

    We would like to thank Dr Cunnington for his interest in our study and raising some potentially interesting points . We do not have a breakdown of patients with heart failure ( HF) who had either preserved (HFpEF) or reduced ejection fraction (HFrEF) . Since beta-blockers only have a licensed indication for HFrEF on the basis of an echocardiogram , we do not believe that this is likely to be a relevant factor within our dataset . The relative prevalence of hypertension within our cohort was 13.3% verses 11.6% ,and for diabetes was 47.4% verses 41.9% respectively for HF alone verses HF with COPD . Hence the assertion made regarding a higher putative comorbidity is not supported by the data presented here . Consequently prescribing of ACEI/ARB in HF with COPD was not confounded by comorbidity due to treatment for either diabetes or hypertension . The higher use of ACEI/ARB without beta-blocker in HF with COPD compared to HF alone is more likely to reflect a reticence of physicians to prescribe add on therapy with beta-blockers in the presence of airflow obstruction due to fears of bronchoconstriction . As such we remain confident in the strength of our conclusions regarding underuse of beta-blockers in HF with COPD .

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response
  10. Impact of Beta-blocker on The Outcome of Takotsubo Cardiomyopathy

    The article by Isogai et al. published in Heart (1) discuss the use of beta-blockers in patients diagnosed and admitted with takotsubo cardiomyopathy (TTC).

    Although no effective guidelines have been prescribed for the treatment of TTC, it is suggested that a parable could be drawn by comparing the use of beta-blocker and angiotensin-converting-enzyme inhibitors in these patients with that of control subjects as well as those suffering from coronary artery disease. Beta-blockers were considered more likely to be prescribed to control subjects and patients diagnosed with coronary artery disease than to patients diagnosed with TTC. Interestingly, TTC and coronary artery disease patients received angiotensin-converting-enzyme inhibitors / angiotensin receptor blockers more often than control subjects. The concluding suggestion that the 5 year mortality is similar in both disease groups and higher than control subjects furthers our debate on this topic. The large International Takotsubo Registry reported a 5.6% mortality per-patient year (2) and the use of angiotensin-converting- enzyme inhibitors or angiotensin receptor- blockers was associated with improved survival rates. However, evidence establishing a marked survival benefit with beta-blocker use has yet to be documented. The pathogenesis of TTC is yet to be fully understood. A popular hypothesis suggests the involvement of a catecholamine-mediated mechanism. Although all these trials essentially compared the outcome of TTC with matched cohorts of patients with coronary artery disease, a relevant suggestion elucidates the role of an inflammatory and energetic- metabolic pathway as a possible pathophysiological mechanism (3). We retrospectively described a collective of 114 consecutive patients diagnosed with TTC between January 2003 and September 2015 at our institution. Our data showed that the use of beta-blocker was associated with improved survival rates over mean follow-up of 5 years (4). These novel findings necessitate the need for a standardized treatment regimen in TTC patients. We recommend the urgent need of randomized trials to clearly define treatment approaches and management strategies in takotsubo cardiomyopathy thus enabling the practice of evidence-based medicine within guidelines.

    References

    1. Isogai T, Matsui H, Tanaka H, et al. Early beta-blocker use and in -hospital mortality in patients with Takotsubo cardiomyopathy. Heart 2016;102(13):1029-1035. 2 . Templin C, Ghadri JR, Diekmann J, et al. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med 2015;373(10):929-938. 3. Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA 2011;306(3):277-286. 4. Becher T, El-Battrawy I, Baumann S, et al. Characteristics and long- term outcome of right ventricular involvement in Takotsubo cardiomyopathy. Int J Cardiol 2016;220:371-375.

    Conflict of Interest: None declared

    Conflict of Interest:

    None declared

    Read all letters published for this article

    Submit response

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of Heart.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.